These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18618379)

  • 1. Adjuvant chemotherapy for colon cancer--analysis of treatment costs from the perspective of statutory sickness funds.
    Görner M; Riemer-Hommel P
    Z Gastroenterol; 2008 Jul; 46(7):681-8. PubMed ID: 18618379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer.
    Goerner M; Riemer-Hommel P
    Onkologie; 2009 Nov; 32(11):647-52. PubMed ID: 19887868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Grothey A; Kleeberg UR; Stauch M; Hieke K
    Z Gastroenterol; 2005 Feb; 43(2):155-61. PubMed ID: 15700205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative cost analysis of outpatient and inpatient rehabilitation for cardiac diseases].
    Zeidler J; Mittendorf T; Vahldiek G; von der Schulenburg JM
    Herz; 2008 Sep; 33(6):440-7. PubMed ID: 19156379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
    Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
    Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
    Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cost analysis of outpatient and inpatient rehabilitation for musculoskeletal diseases in Germany.
    Zeidler J; Mittendorf T; Vahldiek G; Zeidler H; Merkesdal S
    Rheumatology (Oxford); 2008 Oct; 47(10):1527-34. PubMed ID: 18682412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost evaluation of a model for integrated care of seriously mentally ill patients].
    Fischer F; Hoffmann K; Mönter N; Walle M; Beneke R; Negenborn S; Weinmann S; Willich SN; Berghöfer A
    Gesundheitswesen; 2014 Feb; 76(2):86-95. PubMed ID: 23737155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting.
    Douillard JY; Tilleul P; Ychou M; Dufour P; Perrocheau G; Seitz JF; Maes P; Lafuma A; Husseini F
    Oncology; 2007; 72(3-4):248-54. PubMed ID: 18185019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financing in knee arthroplasty: a benchmarking analysis.
    Effenberger H; Rehart S; Zumstein MD; Schuh A
    Arch Orthop Trauma Surg; 2008 Dec; 128(12):1349-56. PubMed ID: 18309508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
    Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
    Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-minimisation analysis of vaginal wall repair in an inpatient or outpatient regimen.
    Sørensen J; Axelsen SM
    Acta Obstet Gynecol Scand; 2007; 86(4):473-9. PubMed ID: 17486471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
    Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
    Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world resource use and costs of adjuvant treatment for stage III colon cancer.
    van Gils CW; de Groot S; Tan SS; Redekop WK; Koopman M; Punt CJ; Uyl-de Groot CA
    Eur J Cancer Care (Engl); 2015 May; 24(3):321-32. PubMed ID: 24372941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in the cost of medications for the treatment of colorectal cancer.
    Ferro SA; Myer BS; Wolff DA; Poniewierski MS; Culakova E; Cosler LE; Scarpace SL; Khorana AA; Lyman GH
    Am J Manag Care; 2008 Nov; 14(11):717-25. PubMed ID: 18999906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Direct medical costs of (severe) obesity: a bottom-up assessment of over- vs. normal-weight adults in the KORA-study region (Augsburg, Germany)].
    von Lengerke T; Reitmeir P; John J
    Gesundheitswesen; 2006 Feb; 68(2):110-5. PubMed ID: 16482491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.